|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19.08.26 - 17:54
|
Moderna Surges on Cancer Vaccine; Estee Lauder Rallies on Earnings | Stock Movers (Bloomberg)
|
|
|
On this episode of Stock Movers:
- Shares of Moderna (MRNA) surged by a record 101% - the stock's biggest intraday gain on record - after the biotech said a personalized cancer vaccine combined with partner Merck & Co.'s Keytruda helped cut the recurrence of melanoma in a large, late-stage trial. The study also met a key secondary goal of showing the shot could help prevent tumors from spreading to new areas of the body, the companies said in a statement Wednesday.
- Shares of Estee Lauder (EL) rallied after the beauty company's adjusted earnings per share and sales metrics topped consensus expectations for the fourth quarter. The midpoint of fiscal 2027 organic sales and adjusted EPS guidance ranges are above Street views.
- Shares of La-Z-Boy (LZB) tumbled at the open after the furniture maker's forecast sales for the second quarter missed the average analyst estimate. (Source: Bloomberg)...
|
|
|
19.08.26 - 16:48
|
433 Prozent Gewinn mit Moderna (Der Aktionaer)
|
|
|
Im Aktien-Report „Hot-Stocks EXTREM“ (vom 12.12.2025) hatte ich im Rahmen eines Ausblicks prognostiziert, dass mRNA-Impfstoffe im Jahr 2026 eine überraschende Renaissance erleben könnten. Im Beitrag „Naht bei Moderna eine Kursexplosion?“ (siehe hierzu die Seite 4; damaliger Kurs: 29,63 Dollar) war zu lesen: „Positiv hingegen: 2026 werden Daten aus der dritten Studienphase für ein Präparat gegen Hautkrebs erwartet, welches in Kombination mit Keytruda (von Merck & Co....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|